Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
Public ClinicalTrials.gov record NCT04655313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, 4-Week, Phase 2, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Pediatric Subjects (Ages 6 to 11 Years Old) With Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 6 to 11 years old) with plaque psoriasis:
Study identification
- NCT ID
- NCT04655313
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years to 11 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2020
- Primary completion
- Jan 11, 2022
- Completion
- Jan 11, 2022
- Last update posted
- Dec 14, 2023
2020 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 6
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arcutis Clinical Site 503 | Mountain Brook | Alabama | 35223 | — |
| Arcutis Clinical Site 504 | Scottsdale | Arizona | 85255 | — |
| Arcutis Clinical Site 509 | Fountain Valley | California | 92708 | — |
| Arcutis Site 518 | Los Angeles | California | 90017 | — |
| Arcutis Clinical Site 508 | Los Angeles | California | 90057 | — |
| Arcutis Clinical Site 511 | Rancho Santa Margarita | California | 92688 | — |
| Arcutis Clinical Site 510 | Boca Raton | Florida | 33428 | — |
| Arcutis Clinical Site 502 | Coral Gables | Florida | 33146 | — |
| Arcutis Clinical Site 513 | Delray Beach | Florida | 33484 | — |
| Arcutis Clinical Site 501 | Hialeah | Florida | 33016 | — |
| Arcutis Clinical Site 507 | Miami | Florida | 33155 | — |
| Arcutis Clinical Site 527 | West Lafayette | Indiana | 47906 | — |
| Arcutis Clinical Site 506 | Arlington | Texas | 76001 | — |
| Arcutis Clinical Site 519 | Frisco | Texas | 75034 | — |
| Arcutis Clinical Site 505 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04655313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04655313 live on ClinicalTrials.gov.